Cue Biopharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cue Biopharma and other ETFs, options, and stocks.

About CUE

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). 

CEO
Shao Lee Lin
CEOShao Lee Lin
Employees
29
Employees29
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
2014
Founded2014
Employees
29
Employees29

CUE Key Statistics

Market cap
123.07M
Market cap123.07M
Price-Earnings ratio
-5.26
Price-Earnings ratio-5.26
Dividend yield
Dividend yield
Average volume
82.27K
Average volume82.27K
High today
$31.52
High today$31.52
Low today
$27.93
Low today$27.93
Open price
$29.37
Open price$29.37
Volume
13.29K
Volume13.29K
52 Week high
$41.42
52 Week high$41.42
52 Week low
$4.97
52 Week low$4.97

Stock Snapshot

With a market cap of 123.07M, Cue Biopharma(CUE) trades at $29.30. The stock has a price-to-earnings ratio of -5.26.

On 2026-06-09, Cue Biopharma(CUE) stock moved within a range of $27.93 to $31.52. With shares now at $29.30, the stock is trading +4.9% above its intraday low and -7.0% below the session's peak.

Trading volume for Cue Biopharma(CUE) stock has reached 13.29K, versus its average volume of 82.27K.

Over the past 52 weeks, Cue Biopharma(CUE) stock has traded between a high of $41.42 and a low of $4.97.

Over the past 52 weeks, Cue Biopharma(CUE) stock has traded between a high of $41.42 and a low of $4.97.

CUE News

TipRanks 6d
Cue Biopharma Shareholders Approve 2026 Stock Incentive Plan

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

TipRanks 7d
Cue Biopharma Streamlines Governance and Strengthens Leadership Team

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

TipRanks 7d
Cue Biopharma announces board transition, appoints two new directors

Cue Biopharma (CUE) announced the transition of its board as the company advances its strategic growth and development efforts. Effective May 29, four independe...

More CUE News

Investing.com 7d
Cue Biopharma stock falls as four directors resign from board - Investing.com

...

Cue Biopharma stock falls as four directors resign from board - Investing.com

People also own

Based on the portfolios of people who own CUE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.